Collplant Biotechnologies Ltd (CLGN) FinancialsCLGNCollplant Biotechnologies Ltd

Collplant Biotechnologies Ltd (CLGN) generates its revenue primarily from Revenues from the sales of goods, which accounts for 100.0% of total sales, equivalent to $179.00K. Understanding this concentration is critical for investors evaluating how CLGN navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Collplant Biotechnologies Ltd maintains a gross margin of -422.22%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -2437.96%, while the net margin is -2524.07%. These profitability ratios, combined with a Return on Equity (ROE) of -161.98%, provide a clear picture of how effectively CLGN converts its operational activities into shareholder value.

In the context of the broader market, CLGN competes directly with industry leaders such as BMRA and NMTC. With a market capitalization of $11.43M, it holds a leading position in the sector. When comparing efficiency, CLGN's gross margin of -422.22% stands against BMRA's 8.14% and NMTC's 59.94%. Such benchmarking helps identify whether Collplant Biotechnologies Ltd is trading at a premium or discount relative to its financial performance.

CollPlant has shown erratic financial performance, with total revenues fluctuating significantly, peaking at $2,055,000 in Q1 2025 and dropping to $60,000 in Q4 2025. The gross margin has been negative in several quarters, indicating ongoing operational challenges. The most recent EPS reported was -1.89, showing continued losses.